


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1814 1624
		Examiner Name	Not Yet Assigned K. Kabk
Sheet 1 of 10	Attorney Docket Number	SYR-DPP-IV-5004-C1	

FEB 23 2005



U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. 1	Document Number		Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)				
KH	AA	US1974/3823135		07-09-1974	Pilgram et al.	
	AB	US1996/5512549		04-30-1996	Chen et al.	
	AC	US1996/5580979		12-03-1996	Bachovchin	
	AD	US1997/5814492		03-25-1997	Habener	
	AE	US2000/6156739		12-5-2000	Griffin et al.	
	AF	US2000/6166063		12-26-2000	Vilhauer	
	AG	US2001/6258597-B1		07-10-2001	Bachovchin	
	AH	US2001/0020006-A1		09-06-2001	Demuth et al.	
	AI	US2001/6303661-B1		10-16-2001	Demuth et al.	
	AJ	US2001/6319893-B1		11-20-2001	Demuth et al.	
	AK	US2001/0051648-A1		12-13-2001	Demuth et al.	
	AL	US2002/0049153-A1		04-25-2002	Bridon et al.	
	AM	US2002/0049184-A1		04-25-2002	Demuth et al.	
	AN	US2002/6380398-B2		04-30-2002	Kanstrup et al.	
	AO	US2002/0082427-A1		06-27-2002	Demuth et al.	
	AP	US2002/6448045-B1		09-10-2002	Levine et al.	
	AQ	US2002/0198242-A1		12-26-2002	Demuth et al.	
	AR	US2002/0198380-A1		12-26-2002	Belzer et al.	
	AS	US2002/6500804-B2		12-31-2002	Demuth et al.	
	AT	US2003/0008925-A1		01-09-2003	Demuth et al.	
	AU	US2003/6548481-B1		04-15-2003	Demuth et al.	
	AV	US2003/0092630-A2		05-15-2003	Demuth et al.	
	AW	US2003/0119750-A1		06-26-2003	Demuth et al.	
	AX	US2003/0130199-A1		07-10-2003	von Hoersten et al.	
	AY	US2003/0134802-A1		07-17-2003	Demuth et al.	
	AZ	US2003/0135023-A1		07-17-2003	Demuth et al.	
	BA	US2003/0148981-A1		08-07-2003	Heiser et al.	
	BB	US2003/0153509-A1		08-14-2003	Bachovchin et al.	
	BC	US2003/0162820-A1		08-28-2003	Demuth et al.	
BD	US2003/0166578-A1		09-04-2003	Arch et al.		
BE	US2003/6620910-B1		09-16-2003	Calas et al.		
BF	US2003/0176357-A1		09-18-2003	Pospisilik et al.		
BG	US2003/0198451-A1		10-23-2003	Mogensen et al.		
BH	US2003/0199872-A1		10-23-2003	Knudsen et al.		

Examiner Signature	<i>A. M. Ph</i>	Date Considered	4/24/2006
-----------------------	-----------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/809,636	
			Filing Date	March 24, 2004	
			First Named Inventor	Jun Feng	
			Group Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C1

KN	BI	US2003/0236272-A1	12-25-2003	Richard David Carr	
	BJ	US2004/8703238-B2	03-09-2004	Bachovchin	
	BK	US2004/0054171-A1	03-18-2004	Jensen et al.	
	BL	US2004/0058876-A1	03-25-2004	Hoffmann et al.	
	BM	US2004/0132732-A1	07-08-2004	Han et al.	
	BN	US2004/0167181-A1	08-28-2004	Demuth et al.	
	BO	US2004/0171555-A1	09-02-2004	Demuth et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KN	BP	FR 2.162.108 (English Abstract-1973)	11-30-1972	Amschler et al.		
	BQ	WO 89/10701	11-16-1989	BASF		
	BR	EP 0378255-A2	07-18-1990	Janssen Pharmaceutica		
	BS	GB 2230527-A	10-24-1990	Imperial Chemical Industries Plc		
	BT	WO 91/12001	08-22-1991	Merck & Co., Inc.		
	BU	WO 93/21162	01-28-1993	Nissan Chemical Industries, Ltd.		
	BV	WO 93/08259 (A2)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BW	WO 93/08259 (A3)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BX	EP 0547442-A1	06-23-1993	E.R. Squibb & Sons, Inc.		
	BY	WO 94/03055	02-17-1994	U.S. Government, Secty. HHS		
	BZ	EP 0587377-A2	03-16-1994	Eli Lilly and Company		
	CA	WO 95/35031	12-28-1995	La Trobe University		
	CB	WO 96/32384	10-17-1996	Taiho Pharmaceutical Co., Ltd.		
	CC	WO 96/38550	12-05-1996	Dana-Farber Cancer Institute, Inc.		
	CD	WO 97/40832	11-06-1997	Hans-Knoll-Institut Fur Naturstoff		
	CE	JP 8285977	11-18-1997	Terumo Corp.		
	CF	WO 98/00439	01-08-1998	Trustees of Tufts College		
	CG	WO 98/24780	06-11-1998	Amgen Inc.		
	CH	WO 99/16864	04-08-1999	Point Therapeutics, Inc.		
	CI	WO 99/38501	08-05-1999	Trustees of Tufts University		

Examiner Signature	<i>At My Ph</i>	Date Considered	4/24/2006
--------------------	-----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 3 of 10	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KN	CJ	WO 99/50249	10-07-1999	Du Pont Pharmaceuticals Company		
	CK	WO 99-61431	12-02-1999	Probiobrug		
	CL	WO 99/67278	12-29-1999	Pro-Biodrug		
	CM	WO 99/67279	12-29-1999	Pro-Biodrug		
	CN	WO 00/07617	02-17-2000	Novo Nordisk		
	CO	WO 00/09668	02-24-2000	U.S. Government, Secty. HHS		
	CP	WO 00/15211	03-23-2000	Akasis Pharmaceuticals, Inc.		
	CQ	WO 00/76988-A1	04-11-2000	Probiobrug		
	CR	WO 00/34241	06-15-2000	Novartis AG		
	CS	WO 00/47219	08-17-2000	Ontogeny, Inc.		
	CT	WO 00/53171	09-14-00	Molteni L. E.C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.		
	CU	WO 00/57721	10-05-2000	Akasis Pharmaceuticals, Inc.		
	CV	WO 01/14318-A2	03-01-2001	Probiobrug		
	CW	WO 01/34594-A1	05-17-2001	Guilford Pharmaceuticals, Inc.		
	CX	WO 01/52825-A2	07-26-2001	Novartis AG		
	CY	WO 01/56988-A1	08-09-2001	Kirin Beer Kabaushiki Kaisha		
	CZ	WO 01/70729-A1	09-27-2001	Sanofi-Synthelabo		
	DA	WO 01/97808-A1	12-27-2001	Smithkline Beecham PLC		
	DB	WO 02/34242-A2	05-02-2002	Probiobrug AG		
	DC	WO 02/34243-A2	05-02-2002	Probiobrug AG		
	DD	WO 02/083109-A1	10-24-2002	Ferring BV		
	DE	JP 2002/338466	11-27-2002	Tanabe Selyaku Co Ltd		
	DF	WO 03/002593-A2	01-09-2003	Probiobrug AG		
	DG	WO 03/002595-A2	01-09-2003	Probiobrug AG		
	DH	WO 03/002598-A2	01-09-2003	Probiobrug AG		
	DI	WO 03/016335-A2	02-27-2003	Probiobrug AG		
	DJ	WO 03/022871-A2	03-20-2003	Probiobrug AG		
	DK	WO 03/026852-A1	04-03-2003	Bristol-Myers Squibb Company		
	DL	WO 03/030948-A1	04-17-2003	Novartis AG		
	DM	WO 03/03524-A2	04-24-2003	Probiobrug AG		
	DN	JP 2003/128551	05-08-2003	Sankyo Co LTD		
	DO	WO 03/040174-A2	05-15-2003	Probiobrug AG		
	DP	WO 03/045228-A2	06-05-2003	Trustees of Tufts College		
	DQ	WO 03/045977-A2	06-05-2003	Trustees of Tufts College		
	DR	WO 03/048081-A2	06-12-2003	Bristol-Myers Squibb Company		
	DS	WO 03/048158-A1	06-12-2003	Bristol-Myers Squibb Company		
	DT	WO 03/057200-A2	07-17-2003	Novo Nordisk		

Examiner Signature	<i>AA my km</i>	Date Considered	4/24/2006
--------------------	-----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 4 of 10	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KH	DU	WO 03/063903-A2	08-07-2003	Probiobug AG		
	DV	WO 03/072558-A1	09-04-2003	Probiobug AG		
	DW	WO 03/082898-A2	10-09-2003	Probiobug AG		
	DX	WO 03/092605-A2	11-13-2003	Trustees of Tufts College		
	DY	WO 03/099279-A1	12-04-2003	Novartis AG		
	DZ	WO 03/099818-A1	12-04-2003	Chiron Corporation		
	EA	WO 03/106416-A2	12-24-2003	SmithKline Beecham Corporation		
	EB	WO 2004/017989-A1	03-04-2004	Probiobug AG		
	EC	JP 2004/89600-A	04-02-2004	Sankyo Co. Ltd.		
	ED	WO 2004/031374-A2	04-15-2004	Probiobug AG		
	EE	JP 2004/123738-A	04-22-2004	Takeda Chem Ind Ltd		
	EF	WO 2004/037178-A2	05-06-2004	Bristol-Myers Squibb Company		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	EG	ARGAUD, DORIANE et al., Metaformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993).	
	EH	ASHCROFT, STEPHEN J.H. et al., Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1986), 89 pp. 469-472.	
	EI	BAL, GUNTHER, Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors, (2002) Universiteit Antwerpen.	
	EJ	BARAKAT, S.E.S., Synthesis and hypoglycemic activity of some new 3-[4- [[(cyclohexylamino) carbonyl] amino]sulfonylphenyl]-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000), pp. 48-57.	
	EK	BARAKAT, S.E.S., Synthesis and Hypoglycemic Activity of Some New 4(3H) -Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 8, No. 4 (2000) pp.189-204.	
	EL	BAKER, B.R. et al., Irreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolate Reductase (1,2), Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48.	
	EM	BELGODERE, ELENA et al., Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9.	
	EN	BEZUGLYI, P.O. et al., Synthesis of arylsulfonyl hydrazide of 3-R-quinazolinone-4-carbonyl-2-acid, Pharmaceutical Journal (1979), pp. 70-71.	

Examiner Signature		Date Considered	4/24/2006
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 5 of 10	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KM	EO	BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazoline (Centipiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414.	
	EP	BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 399-405.	
	EQ	BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity in Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391.	
	ER	BUCKLEY, DI, Analysis of the Degradation of Insulintropin [GLP-1 (7-37)] in Human Plasma and Production of Degradation Resistant Analogs.	
	ES	CHATTERJEE, A.K. et al., Effect of Centipiperalone in Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008.	
	ET	CHATTERJEE, A.K. et al., Effect of Centipiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1981) pp.270-272.	
	EU	COPPOLA, GARY M. et al., 1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors, Bioorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558.	
	EV	DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 <i>in Vitro</i> Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite <i>in Vivo</i> , Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957.	
	EW	DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, Vol. 44 (1996), pp. 1125-1131.	
	EX	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism <i>In Vivo</i> , Regulatory Peptides Vol. 64 Issues 1-3 (1996) p.30.	
	EY	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig, Diabetes, Vol. 47 (1998), pp. 764-769.	
	EZ	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4.	
	FA	DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 298 (2002) pp. 229-232.	
	FB	ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, Proc. Nat. Acad. Sci. Early Edition (2003), pp. 1-6.	
✓	FC	FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects <i>In Vitro</i> and <i>In Vivo</i> , J. Clinical Endocrinology & Metabolism (1986), pp. 899-905.	

Examiner Signature		Date Considered	4/24/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,636
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	6	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	FD	GARRATT, PETER J. et al., A Novel Synthesis of Dihydropyrimidines, J. Chem. Soc., Chem. Commun. (1987), pp.568-569.	
1	FE	GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Dihydropyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, J. Org. Chem. (1988), pp. 1062-1069.	
	FF	GAZIT, AVIV et al., Typhostins IV - Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4- Aryldoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No.8 (1996) pp. 1203-1207.	
	FG	GUERRIERI, N., et al., Vanadium Inhibition of Serine and Cysteine Proteases, Comparative Biochemistry and Physiology Part A 122 (1997), pp.331-338.	
	FH	GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolones and Triazepino-and Triazodolquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395.	
	FI	GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, Nature, Vol. 223 (1969), p. 524.	
	FJ	GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene 5,6)pyrimidines & 3-Substituted 4-Oxo-pyrido [1,2-a] pyrimidines, Indian Journal of Chemistry, Vol. 9 (1971), pp. 201-206.	
	FK	HERMECZ, ISTVAN et al., Pyrido[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, Medicinal Research Reviews, Vol. 8, No. 2 (1988) pp.203-230.	
	FL	HINKE, SIMON A. et al., Metaformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochemical and Biophysical Research Communications, 291 (2002) pp. 1302-1308.	
	FM	HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metaformin and Dipeptidyl Peptidase IV Inhibitors, Diabetes Care, Vol. 25, No. 8 (2002) pp. 1490-1492.	
	FN	HOLZ, GEORGE G. et al, Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1(7-37), Nature, Vol. 381 (1993), pp. 362-365.	
	FO	KHALID, NORAINI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32, Applied and Environmental Microbiology (1990), pp. 381-388.	
	FP	KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependant Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV, Endocrinology, Vol. 138, No. 8 (1995) 3585-3596.	
	FQ	KIMURA, TOSHIKIRO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, Biological & Pharmaceutical Bulletin, Vol. 19, No. 6 (1996), 897-900.	
✓	FR	KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From <i>Prevotella loeschei</i> ATCC 15930, Archives of Oral Biology, 46 (2001), 759-768.	

Examiner Signature		Date Considered	4/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,636
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	7	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C1

KV	FS	KUSAR, MIHAEL et al., Diethyl N,N-Dimethylaminomethylenemalonate in the Synthesis of Fused Heterocyclic Systems, Heterocyclic Chem. 33 (1996) pp. 1041-1046.	
	FT	LI JINPING, et al., Pemolybdate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, Biochemistry, 34 (1995) 6218-6225.	
	FU	LIN, JIAN, Total Synthesis and Biological Evaluation of Fluorolefin-containing Dipeptidyl Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1998).	
	FV	LOESER, ERIC et al., Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, Synthetic Communications, 32(3) (2002) pp. 403-409.	
	FW	MANNUCCI, EDUARDO, et al., Effect of Metformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects, Diabetes Care, Vol. 24, No. 3 (2001) 489-494.	
	FX	MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum, Eur. J. Biochem, Vol. 214, 829-835 (1991).	
	FY	MEYEROVITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, The Journal of Biological Chemistry, Vol. 262, No. 14 (1987) 6658-6662.	
	FZ	MALLOY, J. ARDILL et al., Effect of Metformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, Diabetologia, Vol. 19 (1980) 93-96.	
	GA	MUKERJEE, S.S. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm, Biochemical Pharmacology, Vol. 23 (1974) 3066-3067.	
	GB	MUKERJEE, S.S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, Acta Diabet. Lat 13, 8 (1978) p 8.	
	GC	MUKERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centipiperalone in Rats & Rhesus Monkeys, Indian Journal of Experimental Biology, Vol. 17 (1979) pp. 1348-1349.	
	GD	MUKERJEE, S.S. et al., Tissue Distribution of [³ H]Centipiperalone after Oral Administration, Indian J. Biochem. Biophys., Vol. 17 (1980) pp. 399-401.	
	GE	MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, Biochemical Pharmacology, Vol. 22 (1972) pp. 1529-1531.	
	GF	MUKHERJEE, SURATH K. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats, Biochemical Pharmacology, Vol. 22 (1973) pp. 2205-2206.	
✓	GG	MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, Ind. J. Physiol. & Allied Sci., Vol. 30, No. 3 (1978) pp. 105-116.	

Examiner Signature		Date Considered	4/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,636
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	8	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C1

KY	GH	MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycaemic Agent A-4186 in Relation to Food, Diabetologia Vol. 38 A194 Supplement 1 (1995).	
	GI	MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, Acta Diabet. Lat. 13, 8, (1976) pp. 8-19.	
	GJ	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V - Synthesis & Hypoglycemic Activity of Some New 1-[p-(4-OXO-2-Methyl/Phenyl-3 (4H)-Quinazolinyl) Phenyl] 3-Aryl-2-Ureas, Indian Drugs, 25 (1) (1987) pp. 19-22.	
	GK	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[p-(4-OXO-2-Substituted-3(4H)-Quinazolinyl)-Phenyl] Sulphonyl-3-Aryl/Cyclohexyl-2-Thioureas, Current Science, Vol. 56, No. 24 (1987) pp. 1263-1265.	
	GL	NAKAMURA, SEIJI, et al., Effect of Chronic Vanadate Administration in Partially Depancreatized Rats, Diabetes Research and Clinical Practice 27 (1995) pp. 51-59. (Abstract Only)	
	GM	OHKUBO, I., et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, J. Biochem. (Tokyo) (1994) 116(5) pp. 1182-11826.	
	GN	PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, Pharmacological Research Communications, Vol. 17, No.8 (1985) pp. 699-709.	
	GO	PAULY, R.P. et al., Inhibition of Dipeptidyl Peptidase IV (DPV) in Rat Results in Improved Glucose Tolerance, Regulatory Peptides Vol. 64, Issues 1-3 (1996) p. 148.	
	GP	PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidine, Diabetes, Vol. 47 (1998) pp.1253-1258.	
	GQ	PILLAI, SREEKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, The Journal of Biological Chemistry, Vol. 260, No. 14 (1985) pp. 8384-9.	
	GR	PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62: Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, J. Org. Chem. 51 (1985) 394-399.	
	GS	POJE, M. et al., Diabetogenic action of allozan-like derivatives of uric acid, Experientia 36 (1980) pp. 78-9.	
	GT	POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of 5-Imino-2,4,6-(1H,3H,5H)-pyrimidinetrione Salts and Their Alloxan-like Covalent Adducts, J. Med. Chem. 26 (1983) 881-4.	
	GU	POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, Arzneim.-Forsch./ Drug Res. 28 (1978), 791-93.	
✓	GV	PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide1(7-38)amide in Dogs and is Degraded More Quickly in Vitro by Dog Plasma, European Journal of Drug Metabolism and Pharmacokinetics, Vol. 21 (1995), pp. 51-59.	

Examiner Signature	<i>At M J Ph</i>	Date Considered	4/24/2006
--------------------	------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 9 of 10	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KH	GW	RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Suitably Functionalized 3H-quinazolin-4-ones, Bioorganic & Medicinal Chemistry 11 (2003), pp. 2439-2444.	
	GX	SAWYER, JAMES H. et al., Pyrrolo[1,2-a]pyrimidinium Salts. Part 1. Synthesis from 2- Aminopyridines and Interconversion with 2-(2-Acylvinylamino) pyridines, J.C.S. Perkin I (1972), 1138-1143.	
	GY	SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, Indian Journal of Experimental Biology, Vol. 34 (1996), pp. 351-355.	
	GZ	SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 1550 (2001), pp. 107-116.	
	HA	SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazino-activity of 6-polymethylenepyrimidines, Eur. J. Med. Chem. (1982), 75-79.	
	HB	SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, Bioorganic & Medicinal Chemistry Letters 12 (2002) pp. 2825-2828.	
	HC	SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolones, Indian Journal of Chemistry, Vol. 14B (1975), 538-540.	
	HD	SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, J. Enzyme Inhibition, Vol. 14 (1999) pp. 259-275.	
	HE	SHISHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion in Vitro and in Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozocin-Induced Rats, Diabetes, Vol. 41 (1992), pp. 982-988.	
	HF	SINYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, pp 168-171 (1986), pp. 103-105.	
	HG	SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, Journal of Clinical Investigation, Vol. 46, No.5 (1967) pp. 778-785.	
	HH	SRIVASTAVA, P.P. et al., Efficacy of Centpiperalone in Combination With Biguanide & Sulfonylurea, Indian Journal of Experimental Biology, Vol. 21 (1983), pp. 390-392.	
	HI	TANAKA, KEIJI et al, Vanadate Inhibits the ATP-Dependant Degradation of Proteins in Reticulocytes Without Affecting Ubiquitin Conjugation, The Journal of Biological Chemistry, Vol. 259, No. 4 (1983), 2803-2809.	
	HJ	VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, Annual Reports In Chemistry 36 (2001), 191-200.	
	HK	VILLHAUER, EDWIN B. et al., 1-[[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, J. Med. Chem. 46 (2003), pp. 2774-2789.	

Examiner Signature	<i>Amr Ph</i>	Date Considered	4/24/2006
--------------------	---------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,636
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	10	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C1


KH	HL	WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2689-94.	
	HM	WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes, Current Opinion In Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420.	
	HN	YASUDA, NOBUYUKI et al. Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784.	
	HO	YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rats, Diabetes Research and Clinical Practice 43 (1999), pp. 9-18.	
	HP	ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725.	
	HQ	ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-56.	

Examiner Signature		Date Considered	4/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>1</u> of <u>2</u>			Complete if Known	
			Application Number	10/809,636
			Filing Date	March 24, 2004
			First Named Inventor	Jun FENG
			Group Art Unit	1614 1624
			Examiner Name	K. Habte
			Attorney Docket Number	SYR-DPP-IV-5004-C1

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH ↓ ✓	AA	US1998/5798344	12-25-1998	Kuroki et al.	
	AB	US2002/0169159	11-14-2002	Medina et al.	
	AC	US2003/0069234	4-10-2003	Medina et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KH ↓ ✓	AD	BR 699812	11-29-1950	The Distillers Company Limited		
	AE	53005180 A	01-18-1978	Sumitomo Chem		
	AF	EP 1138482 A1	09-28-2001	Sanofi-Synthelabo		
	AG	WO 01/86285 A2	12-20-2001	Novartis AG		
	AH	WO 02/02580 A2	01-10-2002	Novo Nordisk		
	AI	WO 03/000181 A2	01-03-2003	Merck & Co., Inc.		
	AJ	WO 03/007888 A2	01-30-2003	Adipogenix, Inc.		
	AK	WO 03/027080 A1	04-03-2003	Mitsubishi Pharma		
	AL	WO 03/037888 A1	05-08-2003	Mitsubishi Pharma		
	AM	WO 03/078418 A1	09-18-2003	X-Ceptor Therapeutics, Inc.		
	AN	WO 04/062613 A2	07-28-2004	Bristol-Myers Squibb		
	AO	WO 04/085408 A1	10-07-2004	Mitsubishi Pharma		

Examiner Signature		Date Considered	4/24/2006
-----------------------	--	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1614
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	SYR-DPP-IV-5004-C1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KN	AP	DEY, PARAMITA D., et al., Regioselective [4+2] Cycloaddition versus Nucleophilic Reactions of N-Arylamino Substituted 1,3-Diaza-1,3-Butadienes with Ketenes: Synthesis of Pyrimidinone and Fused Pyrimidine Derivatives. Part II. Tetrahedron, Vol. 53, No. 40, pp. 13829-13840, 1997.	
	AQ	JAKUBKIENE, VIRGINIA, et al., (G-Methyl-2-methylsulfanyl-4-oxo-3,4-dihydro-3-pyrimidinyl)acetic acid and related compounds exhibiting anti-inflammatory activity. Pharmazie 57 (2002) 9, pp. 610-613.	
	AR	JONES, TERENCE R., et al., Azafluorenes Containing Two Bridgehead Nitrogen Atoms. Journal of the Chemical Society, Perkin Transactions 1, No. 12, December 1987, pp. 2585-2592.	
	AS	SHARMA, ARUN K., et al. Tandem sigmatropic shifts in [4 + 2] cycloaddition reactions of 1,3-diazabuta-1,3-dienes with butadienyketene: synthesis of pyrimidinone derivatives. J. Chem. Soc., Perkin Trans. 1, 2002, 774-784.	
	AT	Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften. XP-002310120. Beilstein Registry Number 638238 & Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1, 1988, page 92.	
	AU	Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften. XP-002310119. Beilstein Registry Number 649497 & J. Pharm. Sci. Vol. 80, No. 7, 1991, pp. 705-708.	
	AV	Database CA Online Chemical Abstracts Service, Columbus, OH, US; Trochuetz, Reinhard et al., The reaction of O-functional benzylmalononitriles with N-bisnucleophiles as well as alcohols. XP-002311761 retrieved from STN Database accession No. 1994:217538 abstract & Archiv Der Pharmazie (Winheim, Germany), 328(11), 865-9 Coden: ARPMAS; ISSN: 0365-6233, 1993.	
	AW	Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften. XP-002310121. Beilstein Registry Number 7289032 & Nucleosides Nucleotides, Vol. 14, No. 3-5, 1995, pp. 653-656.	
	AX	Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften. XP-002310118. Beilstein Registry Number 7643826 & KHIM. Geterotsikl. Soedin., Vol. 32, No. 5, 1998, pp. 703-707.	
✓	AY	Database Crossfire Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften. XP-002310117. Beilstein Registry Number 8373244 & KHIM. Geterotsikl. Soedin., No. 8, 1998, pp. 1125-1129.	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/24/2006
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

9/14/2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number 10/809,636
 Filing Date March 24, 2004
 First Named Inventor Jun FENG
 Group Art Unit 1624
 Examiner Name Kahsay Habte
 Attorney Docket Number SYR-DPP-IV-5004-C1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
------------------------	--------------------------	---	---	--	---

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document Country Code ² - Number ² - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
KH	AA	WO 03/035057 A	05/01/2003	Ferring B.V.		
J	AB	DE 21 50 686 A1	4/19/1973	Badische Anilin & Soda Fabrik AG		
J	AC	EP 0 442 473 A	08/21/1991	Takeda Chemical Industries, Ltd.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	AD	WEBER, A.E.: Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes, Journal of Medicinal Chemistry, vol. 47, 2004 pages 4135-4141, XP002328845	
J	AE	Patent Abstracts of Japan, vol. 2003, no. 12, Xanthine Derivative, December 5, 2003 & JP 2003 300977 A (Sumitomo Pharmaceut Co Ltd), October 21, 2003, Abstract	
J	AF	BOTTA, M., SALADINO, R., LAMBA, D. NICOLETTI, R.: Researches on Antiviral Agents. 31. Synthesis and Transformations of Racemic and Chiral 6-Oxdranyl Pyrimidinones, Tetrahedron, vol. 49, 1993, pages 6053-6070, XP002328846	
J	AG	FRAISSE, L., et al. Long-Chained Substituted Uric Acid and 5,6-Diaminouracil Derivatives as Novel Agents against Free Radical Processes: Synthesis and In Vitro Activity, Journal of Medicinal Chemistry, vol. 36, 1993, pages 1456-1473, XP002328847	
J	AH	KIM, H.O. et al., Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A ₂ Adenosine Receptors, Journal of Medicinal Chemistry, vol. 37, 1994, pages 3373-3382, XP002328848	

Examiner
Signature

[Handwritten Signature]

Date
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

APR 04 2006

PTO/SB/D&A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 14

Complete if Known

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH	AA	US 3,960,949	6/1/1976	Ahrens, Hanns et al.	
	AB	US 4,494,978	1/22/1985	Chan, David C. K.;	
	AC	US 4,935,493	6/19/1990	Bachovchin, William W. et al.	
	AD	US 5,366,882	11/22/1994	Venton, Duane L. et al.	
	AE	US 5,387,512	02/07/1995	Balani, Suresh K. et al.	
	AF	US 5,433,955	7/18/1995	Bradehorst, Reinhard et al.	
	AG	US 5,462,928	10/31/1995	Bachovchin, William W. et al.	
	AH	US 5,543,396	8/6/1996	Powers, James C. et al.	
	AI	US 5,601,986	2/11/1997	Takacs, Laszlo	
	AJ	US 5,614,379	3/25/1997	MacKellar, Warren C.	
	AK	US 5,624,884	4/29/1997	Bodor, Nicholas S.	
	AL	US 5,811,278	09/22/1998	Okamura, Hideki et al.	
	AM	US 5,811,281	09/22/1998	Quaroni, Andrea et al.	
	AN	US 5,814,460	9/29/1998	Venton, Duane L. et al.	
	AO	US 5,885,997	3/23/1999	Lohray, Vidya Bhushan et al.	
	AP	US 5,939,560	8/17/1999	Jenkins, Paul D. et al.	
	AQ	US 5,965,532	10/12/1999	Bachovchin, William W.	
	AR	US 5,985,884	11/16/1999	Lohray, Vidya Bhushan et al.	
	AS	US 6,006,753	12/28/1999	Efendic, Suad	
	AT	US 6,011,155	1/4/2000	Vilhauer, Edwin Bernard	
	AU	US 6,090,786	7/18/2000	Augustyns, Koen Jan Ludovicus et al.	
	AV	US 6,107,317	8/22/2000	Vilhauer, Edwin Bernard	
	AW	US 6,110,949	8/29/2000	Vilhauer, Edwin Bernard	
	AX	US 6,124,305	9/26/2000	Vilhauer, Edwin Bernard	
	AY	US 6,129,911	10/10/2000	Faris, Ronald A.	
	AZ	US 2001/0018210	8/30/2001	Bachovchin, William et al.	
	BA	US 2001/0031780	10/18/2001	Kanstrup, Anders et al.	
	BB	US 2001/0047078	11/29/2001	Chang, Yie-Hwa	
	BC	US 6,172,081	1/9/2001	Damon, Robert	
	BD	US 6,184,020	2/6/2001	Blinkovsky, Alexander et al.	
	BE	US 6,201,132	3/13/2001	Jenkins, Paul D. et al.	
	BF	US 6,214,340	4/10/2001	Takeuchi, Tomio et al.	
	BG	US 6,235,493	5/22/2001	Bissell, Eugene R. et al.	
	BH	US 6,251,391	6/26/2001	Wilkinson, Randall Eugene et al.	

Examiner
SignatureDate
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **14****Complete if Known**

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KN	BI	US 6,261,794	7/17/2001	Chang, Yie-Hwa	
	BJ	US 6,265,551	7/24/2001	Duke-Cohan, Jonathan S. et al.	
	BK	US 6,309,868	10/30/2001	Monod, Michel	
	BL	US 6,310,069	10/30/2001	Lohray, Vidya Bhushan et al.	
	BM	US 6,325,989	12/4/2001	Duke-Cohan, Jonathan S. et al.	
	BN	US 2002/0068899	1/17/2002	Pospisilik, Andrew J. et al.	
	BO	US 2002/0019411	2/14/2002	Robt, Jeffrey A. et al.	
	BP	US 2002/0037829	3/28/2002	Aronson, Peter S. et al.	
	BQ	US 2002/0041871	4/11/2002	Brudnak, Mark A.	
	BR	US 2002/0061839	5/23/2002	Scharpe, Simon Lodewijk et al.	
	BS	US 2002/0071838	6/13/2002	Demuth, Hans-Ulrich et al.	
	BT	US 2002/0077340	06/20/2002	Sulsky, Richard et al.	
	BU	US 2002/0082292	8/27/2002	Sahoo, Soumya P. et al.	
	BV	US 2002/0103242	8/1/2002	Sahoo, Soumya P. et al.	
	BW	US 2002/0103384	8/1/2002	Kanstrup, Anders et al.	
	BX	US 2002/0110560	8/15/2002	Demuth, Hans-Ulrich et al.	
	BY	US 2002/0115843	08/22/2002	Oi, Steve et al.	
	BZ	US 2002/0132979	9/19/2002	Chen, Wen-Tien	
	CA	US 2002/0147130	10/10/2002	Huber, Brigitte T. et al.	
	CB	US 2002/0147157	10/10/2002	Connor, Gregory S.	
	CC	US 2002/0155565	10/24/2002	Garin-Chesa, Pilar et al.	
	CD	US 2002/0161100	02/07/2002	Okabe, Toshiaki et al.	
	CE	US 2002/0164759	11/7/2002	Travis, James et al.	
	CF	US 2002/0165164	11/7/2002	Demuth, Hans-Ulrich et al.	
	CG	US 2002/0183367	12/5/2002	Sulsky, Richard B. et al.	
	CH	US 2002/0193390	12/19/2002	Villhauer, Edwin Bernard	
	CI	US 2002/0198205	12/26/2002	Himmelsbach, Frank et al.	
	CJ	US 6,335,429	1/1/2002	Cai, Sui Xiong et al.	
	CK	US 6,337,069	1/8/2002	Grouzmann, Eric et al.	
	CL	US 6,342,611	1/29/2002	Weber, Eckard et al.	
	CM	US 6,355,614	3/12/2002	Wallner, Barbara P	
	CN	US 6,395,767	5/28/2002	Robt, Jeffrey A. et al.	
	CO	US 6,432,969	8/13/2002	Villhauer, Edwin Bernard	
	CP	US 6,447,772	9/10/2002	Houston, Devin B.	
	CQ	US 6,458,924	10/1/2002	Knudsen, Liseotte Bjerre et al.	
	CR	US 6,485,955	11/26/2002	Huber, Brigitte T. et al.	
	CS	US 6,495,544	12/17/2002	Hansen, Jr., Donald W. et al.	
✓	CT	US 2003/0008905	1/9/2003	Demuth, Hans-Ulrich et al.	

Examiner
SignatureDate
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **14****Complete If Known**

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	CU	US 2003/0027282	2/8/2003	Huber, Brigitte T. et al.	
	CV	US 2003/0040478	2/27/2003	Drucker, Daniel J. et al.	
	CW	US 2003/0045484	3/8/2003	Hermeling, Ronald Norbert et al.	
	CX	US 2003/0055052	3/20/2003	Peters, Stefan et al.	
	CY	US 2003/0080412	3/27/2003	Prouty, Walter Francis et al.	
	CZ	US 2003/0080434	3/27/2003	Nielsen, Loretta et al.	
	DA	US 2003/0087935	5/8/2003	Cheng, Peter T. et al.	
	DB	US 2003/0087950	5/8/2003	DeNanteuil, Guillaume et al.	
	DC	US 2003/0089935	5/15/2003	Fan, Tso-Hung et al.	
	DD	US 2003/0092897	5/15/2003	Cheng, Peter T. et al.	
	DE	US 2003/0098848	5/22/2003	Cheng, Peter T. et al.	
	DF	US 2003/0098857	5/22/2003	Evans, David Michael et al.	
	DG	US 2003/0100563	5/28/2003	Edmondson, Scott D. et al.	
	DH	US 2003/0103968	6/5/2003	Amelsberg, Andree et al.	
	DI	US 2003/0105077	6/5/2003	Kanstrup, Anders Bendtz et al.	
	DJ	US 2003/0119736	6/26/2003	Demuth, Hans-Ulrich et al.	
	DK	US 2003/0119738	6/26/2003	Niestroj, Andre et al.	
	DL	US 2003/0125304	7/3/2003	Demuth, Hans-Ulrich et al.	
	DM	US 2003/0130281	7/10/2003	Boehringer, Markus et al.	
	DN	US 2003/0130306	7/10/2003	Devasthale, Pratik et al.	
	DO	US 2003/0139429	7/24/2003	Cohen, David Saul et al.	
	DP	US 2003/0139434	7/24/2003	Balkan, Bork et al.	
	DQ	US 2003/0144206	7/31/2003	Knudsen, Lotte Bjerre et al.	
	DR	US 2003/0149071	8/7/2003	Gobbi, Luca Claudio et al.	
	DS	US 2003/0166682	9/4/2003	Fryburg, David Albert et al.	
	DT	US 2003/0166690	9/4/2003	Ebdrup, Soren et al.	
	DU	US 2003/0171358	9/11/2003	Jeppesen, Lone et al.	
	DV	US 2003/0171411	9/11/2003	Kodra, Janos Tibor et al.	
	DW	US 2003/0181497	9/25/2003	Chen, Ping et al.	
	DX	US 2003/0188963	10/2/2003	Dorwald, Florencio Zaragoza et al.	
	DY	US 2003/0187254	10/2/2003	Perry, David A. et al.	
	DZ	US 2003/0191112	10/9/2003	Dorwald, Florencio Zaragoza et al.	
	EA	US 2003/0195188	10/16/2003	Boehringer, Markus et al.	
	EB	US 2003/0195190	10/16/2003	Peschke, Bernd et al.	
	EC	US 2003/0199528	10/23/2003	Kanstrup, Anders B. et al.	
	ED	US 2003/0199563	10/23/2003	Robt, Jeffrey A. et al.	
	EE	US 2003/0203946	10/30/2003	Behrens, Carsten et al.	
✓	EF	US 2003/0218382	11/20/2003	Boehringer, Markus et al.	

Examiner Signature		Date Considered	4/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **4** of **14****Complete If Known**

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KK	EG	US 2003/0216450	11/20/2003	Evans, David Michael et al.	
	EH	US 2003/0220345	11/27/2003	Hamby, James Marino et al.	
	EI	US 2003/0225102	12/4/2003	Senkaranarayanan, Alangudi	
	EJ	US 2003/0232761	12/18/2003	Hinke, Simon A. et al.	
	EK	US 6,521,644	2/18/2003	Broqua, Pierre	
	EL	US 6,528,488	3/4/2003	Larsen, Bjarne Due et al.	
	EM	US 6,545,170	4/8/2003	Pitzele, Barnett S et al.	
	EN	US 6,548,529	4/15/2003	Robl, Jeffrey A. et al.	
	EO	US 6,555,519	4/29/2003	Washburn, William N.	
	EP	US 6,555,521	4/29/2003	Hermeling, Ronald Norbert et al.	
	EQ	US 6,559,188	5/6/2003	Gatlin, Marjorie Regan et al.	
	ER	US 6,573,086	6/3/2003	Chen, Wen-Tien	
	ES	US 6,573,287	6/3/2003	Sutsky, Richard B. et al.	
	ET	US 6,588,198	7/1/2003	Brown, Nancy J.	
	EU	US 6,608,038	8/19/2003	Caplan, Shari L. et al.	
	EV	US 6,617,340	9/8/2003	Villhauer, Edwin Bernard	
	EW	US 6,620,821	9/16/2003	Robl, Jeffrey A.	
	EX	US 6,627,636	9/30/2003	Robl, Jeffrey A.	
	EY	US 6,645,995	11/11/2003	Kanstrup, Anders et al.	
	EZ	US2004/0002495	1/1/2004	Sher, Philip et al.	
	FA	US2004/0002609	1/1/2004	Hulin, Bernard	
	FB	US2004/0006082	1/8/2004	Smallheer, Joanne M. et al.	
	FC	US2004/0009972	1/15/2004	Ding, Charles Z. et al.	
	FD	US2004/0009998	1/15/2004	Dhar, T. G. Murali et al.	
	FE	US2004/0034014	2/19/2004	Kanstrup, Anders Bendtz et al.	
	FF	US2004/0053369	3/18/2004	Abbott, Catherine Anne et al.	
	FG	US2004/0063935	4/1/2004	Yasuda, Kosuke	
	FH	US2004/0072874	4/15/2004	Sato, Nagaaki et al.	
	FI	US2004/0072892	4/15/2004	Fukushima, Hiroshi et al.	
	FJ	US2004/0077645	4/22/2004	Himmelsbach, Frank et al.	
	FK	US2004/0082497	4/29/2004	Evans, David Michael et al.	
	FL	US2004/0082607	04/29/2004	Oi, Satoru et al.	
	FM	US2004/0087587	5/6/2004	Himmelsbach, Frank et al.	
	FN	US2004/0092478	5/13/2004	Rothermel, John D. et al.	
	FO	US2004/0097510	5/20/2004	Himmelsbach, Frank et al.	
	FP	US2004/0106855	6/3/2004	Kitajima, Hiroshi et al.	
	FQ	US2004/0106856	6/3/2004	Ashton, Wallace T. et al.	
	FR	US2004/0106802	6/3/2004	Senkaranarayanan, Alangudi et al.	

Examiner Signature		Date Considered	4/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **5** of **14****Complete If Known**

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	FS	US2004/0110817	6/10/2004	Hulin, Bernard	
	FT	US2004/0116328	6/17/2004	Yoshikawa, Seiji et al.	
	FU	US2004/0132713	7/8/2004	Hulin, Bernard et al.	
	FV	US2004/0138148	7/15/2004	Fushimi, Nobuhiko et al.	
	FW	US2004/0138214	7/15/2004	Himmelsbach, Frank et al.	
	FX	US2004/0138215	7/15/2004	Eckhardt, Matthias et al.	
	FY	US2004/0147434	7/29/2004	Ansorge, Siegfried et al.	
	FZ	US2004/0152192	8/5/2004	Bachovchin, William et al.	
	GA	US2004/0152745	8/5/2004	Jackson, Paul et al.	
	GB	US2004/0186125	8/26/2004	Himmelsbach, Frank et al.	
	GC	US2004/0187133	8/26/2004	Edmondson, Scott D. et al.	
	GD	US2004/0187341	8/26/2004	Haffner, Curt Dale et al.	
	GE	US2004/0171104	9/2/2004	Blinkovsky, Alexander et al.	
	GF	US2004/0171848	9/2/2004	Haffner, Curt Dale et al.	
	GG	US2004/0178406	9/8/2004	Gobbi, Luca Claudio et al.	
	GH	US2004/0178428	9/8/2004	Edmondson, Scott D et al.	
	GI	US2004/0180925	9/16/2004	Matsuno, Kenji et al.	
	GJ	US2004/0186153	9/23/2004	Yasuda, Nobuyuki et al.	
	GK	US2004/0198788	10/7/2004	Gretzke, Dirk et al.	
	GL	US2004/0209891	10/21/2004	Broqua, Pierre et al.	
	GM	US2004/0228820	11/18/2004	Bachovchin, William W. et al.	
	GN	US2004/0228848	11/18/2004	Demuth, Hans-Ulrich et al.	
	GO	US2004/0236102	11/25/2004	Brockunier, Linda et al.	
	GP	US2004/0242566	12/2/2004	Feng, Jun et al.	
	GQ	US2004/0242568	12/2/2004	Feng, Jun et al.	
	GR	US2004/0242638	12/2/2004	Haffner, Curt Dale et al.	
	GS	US2004/0242898	12/2/2004	Hulin, Bernard et al.	
	GT	US2004/0254167	12/16/2004	Bifu, Tesfaye et al.	
	GU	US2004/0254226	12/16/2004	Feng, Jun et al.	
	GV	US2004/0259843	12/23/2004	Madar, David J. et al.	
	GW	US2004/0259870	12/23/2004	Feng, Jun et al.	
	GX	US2004/0259883	12/23/2004	Sakashita, Hiroshi et al.	
	GY	US2004/0259902	12/23/2004	Boehringer, Markus et al.	
	GZ	US2004/0259903	12/23/2004	Boehringer, Markus et al.	
	HA	US2004/0259919	12/23/2004	Magnin, David R. et al.	
	HB	US 6,873,815	1/6/2004	Devasthale, Pratik et al.	
	HC	US 6,873,829	1/6/2004	Dorwald, Florencio Zaragoza et al.	
✓	HD	US 6,888,337	2/3/2004	Connor, Gregory S.	

Examiner
SignatureDate
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
Sheet 6 of 14	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KH	HE	US 6,699,871	3/2/2004	Edmondson, Scott D. et al.	
	HF	US 6,706,742	3/16/2004	De Nanteuil, Guillaume et al.	
	HG	US 6,710,040	3/23/2004	Hulin, Bernard et al.	
	HH	US 6,716,843	4/6/2004	De Nanteuil, Guillaume et al.	
	HI	US 6,727,261	4/27/2004	Gobbi, Luca Claudio et al.	
	HJ	US 6,727,271	4/27/2004	Cheng, Peter T. et al.	
	HK	US 6,800,650	10/5/2004	Boehringer, Markus et al.	
	HL	US 6,803,357	10/12/2004	Bachovchin, William A. et al.	
	HM	US 6,825,169	11/30/2004	Bachovchin, William W. et al.	
	HN	US2005/0014732	1/20/2005	Guve, Eric Arthur et al.	
	HO	US2005/0014946	1/20/2005	Demuth, Hans-Ulrich et al.	
	HP	US2005/0020574	1/27/2005	Hausel, Norbert et al.	
	HQ	US2005/0026921	2/3/2005	Eckhardt, Matthias et al.	
	HR	US2005/0032804	2/10/2005	Cypes, Stephen Howard et al.	
	HS	US2005/0038020	2/17/2005	Hamann, Lawrence G. et al.	
	HT	US2005/0043292	2/24/2005	Parker, Janice C. et al.	
	HU	US2005/0043299	2/24/2005	Evans, David M. et al.	
	HV	US2005/0058635	3/17/2005	Demuth, Hans-Ulrich et al.	
	HW	US 6,881,440	3/1/2005	Boehringer, Markus et al.	
	HX	US 6,887,205	3/15/2005	Boehringer, Markus et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ^a - Number ^a - Kind Code ^b (if known)				
KH	HY	DE 2361551A1	6/19/1975	BASF AG		
	HZ	DE 2500024A1	7/8/1978	BASF AG		
	IA	EP 0505893	9/30/1992	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IB	EP 0547514	6/23/1993	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IC	EP 0574846	12/22/1993	MERCK PATENT GmbH		

Examiner Signature	<i>AA My Ph</i>	Date Considered	4/24/2006
-----------------------	-----------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
Sheet 7 of 14	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KH	ID	EP 0657452	6/14/1995	MERCK PATENT GmbH		
	IE	EP 0702013	3/20/1996	MERCK PATENT GmbH		
	IF	GB 1441665A	7/7/1978	COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION		
	IG	WO 91/11457	8/8/1991	BUCKLEY, Douglas, I. Et al.		
	IH	WO 95/15309	6/8/1995	FERRING B.V.		
	II	WO 95/29691	11/9/1995	GEORGIA TECH RESEARCH CORPORATION		
	IJ	WO 96/02687	2/1/1996	AMGEN INC.		
	IK	WO 98/18783	5/7/1998	TANABE SEIYAKU CO., LTD.		
	IL	WO 98/19998	5/14/1998	NOVARTIS AG		
	IM	WO 98/50046	11/12/1998	TRUSTEES OF TUFTS COLLEGE		
	IN	WO 98/51803	11/19/1998	NOVO NORDISK BIOTECH, INC.		
	IO	WO 99/02705	1/21/1999	SOCIETE DES PRODUITS NESTLE S.A.		
	IP	WO 99/17799	4/15/1999	TRUSTEES OF TUFTS COLLEGE ET AL.		
	IQ	WO 99/18856	4/22/1999	CYTOVIA, INC.		
	IR	WO 99/28474	6/10/1999	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES		
	IS	WO 99/46272	9/16/1999	FONDATECH BENELUX N.V.		
	IT	WO 99/47152	9/23/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH		
	IU	WO 99/62914	12/8/1999	POINT THERAPEUTICS, INC.		
	IV	WO 00/10549	3/2/2000	POINT THERAPEUTICS, INC.		
	IW	WO 00/20416	4/13/2000	GANTE, Helga		
	IX	WO 00/40583	7/13/2000	MERCK PATENT GMBH		
	IY	WO 00/43366	7/27/2000	KIRIN BEER KABUSHIKI KAISHA		
	IZ	WO 00/56296	9/28/2000	FERRING BV		
	JA	WO 00/56297	9/28/2000	FERRING B.V.		
	JB	WO 01/16301	3/8/2001	TUFTS UNIVERSITY		

Examiner Signature	<i>[Signature]</i>	Date Considered	4/24/2006
-----------------------	--------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8

of

14

Complete if Known

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	JC	WO 01/19866	3/22/2001	THE UNIVERSITY OF SYDNEY		
	JD	WO 01/40180	6/7/2001	FERRING BV		
	JE	WO 01/55105	8/2/2001	NOVO NORDISK A/S		
	JF	WO 01/62266	8/30/2001	NOVO NORDISK A/S		
	JG	WO 01/68603	9/20/2001	BRISTOL-MYERS SQUIBB CO.		
	JH	WO 01/72290	10/4/2001	PROBIODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH		
	JI	WO 01/74299	10/11/2001	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK		
	JJ	WO 01/79206	10/25/2001	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED		
	JK	WO 01/81304	11/1/2001	FERRING BV		
	JL	WO 01/81337	11/1/2001	FERRING B.V.		
	JM	WO 01/89569	11/29/2001	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH IMTM		
	JN	WO 01/94597	12/13/2001	PROZYMEX /VS		
	JO	WO 02/04610	1/17/2002	BAYER AKTIENGESELLSCHAFT		
	JP	WO 02/051836	7/4/2002	KYOWA HAKKO KOGYO CO., LTD		
	JQ	WO 02/053170	7/11/2002	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM		
	JR	WO 02/058301	8/1/2002	K.U. LEUVEN RESEARCH AND DEVELOPMENT		
	JS	WO 02/059343	8/1/2002	VANDERBILT UNIVERSITY		
	JT	WO 02/062764	8/15/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	JU	WO 02/066627	8/29/2002	BAYER AKTIENGESELLSCHAFT		
	JV	WO 02/068420	9/6/2002	BOEHRINGER INGELHEIM PHARMA KG		
	JW	WO 02/076450	10/3/2002	MERCK & CO., INC.		
	JX	WO 02/083128	10/24/2002	BRISTOL-MYERS SQUIBB COMPANY		
	JY	WO 02/08931	1/31/2002	TEN SQUARE		
	JZ	WO 02/092127	11/21/2002	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
✓	KA	WO 02/096357	12/5/2002	BRISTOL-MYERS SQUIBB COMPANY		

Examiner
Signature

AA W/Th

Date
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
		Attorney Docket Number	SYR-DPP-IV-5004-C1
Sheet	9	of	14

KH	KB	WO 02/14271	2/21/2002	WELFIDE CORPORATION		
	KC	WO 02/20804	3/14/2002	PROZYMEX A/S		
	KD	WO 02/26703	4/4/2002	PROLIFIX LIMITED		
	KE	WO 02/28742	4/11/2002	JOHANSSON, Thomas		
	KF	WO 02/30890	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KG	WO 02/30891	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KH	WO 02/31134	4/18/2002	FERRING BV		
	KI	WO 02/34900	5/2/2002	THE UNIVERSITY OF SYDNEY		
	KJ	WO 02/38541	5/16/2002	TAISHO PHARMACEUTICAL CO., LTD.		
	KK	WO 02/38742	5/16/2002	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.		
	KL	WO 03/000180	1/3/2003	MERCK & CO., INC.		
	KM	WO 03/000250	1/3/2003	FERRING BV		
	KN	WO 03/002530	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KO	WO 03/002531	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KP	WO 03/002553	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KQ	WO 03/004498	1/16/2003	NOVO NORDISK A/S		
	KR	WO 03/004498	1/16/2003	MERCK & CO., INC.		
	KS	WO 03/010197	2/6/2003	GENSET S.A.		
	KT	WO 03/010314	2/6/2003	GENSET S.A.		
	KU	WO 03/011807	2/13/2003	NOVO NORDISK A/S		
	KV	WO 03/011814	2/13/2003	NOVO NORDISK A/S		
	KW	WO 03/011834	2/13/2003	NOVO NORDISK A/S		
	KX	WO 03/011892	2/13/2003	THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	KY	WO 03/014318	2/20/2003	GENZYME CORPORATION		
	KZ	WO 03/015775	2/27/2003	PROBIODRUG AG		
	LA	WO 03/017836	3/6/2003	YALE UNIVERSITY		
✓	LB	WO 03/024942	3/27/2003	MITSUBISHI PHARMA CORPORATION		

Examiner Signature	<i>AA my m</i>	Date Considered	4/24/2006
--------------------	----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **10** of **14****Complete if Known**

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	LC	WO 03/024965	3/27/2003	NOVO NORDISK A/S		
	LD	WO 03/035067	5/1/2003	FERRING B.V.		
	LE	WO 03/037327	5/8/2003	F. HOFFMANN-LA-ROCHE AG		
	LF	WO 03/038123	5/8/2003	NOVARTIS AG		
	LG	WO 03/040114	5/15/2003	BRISTOL-MYERS SQUIBB COMPANY		
	LH	WO 03/051848	6/26/2003	FERRING BV		
	LI	WO 03/053330	3/7/2003	ASTRAZENECA AB		
	LJ	WO 03/055881	7/10/2003	F. HOFFMANN-LA ROCHE AG		
	LK	WO 03/057144	7/17/2003	GUILFORD PHARMACEUTICALS		
	LL	WO 03/057666	7/17/2003	GUILFORD PHARMACEUTICALS		
	LM	WO 03/065983	8/14/2003	MERCK & CO., INC.		
	LN	WO 03/068748	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LO	WO 03/068757	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LP	WO 03/072197	9/4/2003	PFIZER PRODUCTS INC.		
	LQ	WO 03/074500	9/12/2003	SANOFI-SYNTHELABO		
	LR	WO 03/076393	9/18/2003	NOVARTIS AG		
	LS	WO 03/077935	9/25/2003	IMTM INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH,		
	LT	WO 03/080070	10/2/2003	NOVARTIS AG		
	LU	WO 03/080633	10/2/2003	NIPPON KAYAKU KABUSHIKI KAISHA		
	LV	WO 03/082817	10/9/2003	MERCK & CO., INC.		
	LW	WO 03/082859	10/9/2003	NOVARTIS AG		
	LX	WO 03/084940	10/16/2003	SANKARANARAYANAN, Alangudi		
	LY	WO 03/101449	12/11/2003	PFIZER PRODUCTS INC.		
	LZ	WO 03/101958	12/11/2003	PFIZER PRODUCTS INC.		
	MA	WO 03/104207	12/18/2003	MERCK & CO., INC.		
	MB	WO 03/104208	12/18/2003	MERCK & CO., INC.		
	MC	WO 03/104229	12/18/2003	EISAI CO., LTD.		

Examiner
Signature*Amy H*Date
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 14

Complete if Known

Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	MD	WO 03/108458	12/24/2003	SANOI-SYNTHELABO		
	ME	WO 04/002535	1/8/2004	HORMOS MEDICAL CORPORATION		
	MF	WO 04/002986	1/8/2004	BANYU PHARMACEUTICAL CO., LTD.		
	MG	WO 04/004855	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MH	WO 04/004861	1/15/2004	POINT THERAPEUTICS, INC.		
	MI	WO 04/004865	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MJ	WO 04/007448	1/22/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	MK	WO 04/007488	1/22/2004	MERCK & CO., INC.		
	ML	WO 04/011840	2/5/2004	TANABE SEIYAKU CO., LTD.		
	MM	WO 04/014860	2/19/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	MN	WO 04/018467	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MO	WO 04/018468	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MP	WO 04/018469	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MQ	WO 04/020407	3/11/2004	TAISHO PHARMACEUTICAL CO., LTD.		
	MR	WO 04/024184	3/25/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	MS	WO 04/026822	4/1/2004	ABBOTT LABORATORIES		
	MT	WO 04/028524	4/8/2004	EISAI CO., LTD.		
	MU	WO 04/031175	4/15/2004	BANYU PHARMACEUTICAL CO., LTD.		
	MV	WO 04/032836	4/22/2004	MERCK & CO., INC.		
	MW	WO 04/032861	4/22/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MX	WO 04/033455	4/22/2004	NOVO NORDISK A/S		
	MY	WO 04/037169	5/8/2004	MERCK & CO., INC.		
	MZ	WO 04/037181	5/8/2004	BRISTOL-MYERS SQUIBB COMPANY		
	NA	WO 04/041795	5/21/2004	GUILFORD PHARMACEUTICALS INC.		
	NB	WO 04/043940	5/27/2004	MERCK & CO., INC.		
	NC	WO 04/046108	6/3/2004	PFIZER PRODUCTS INC.,		

Examiner
Signature*[Handwritten Signature]*Date
Considered

4/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/809,636	
			Filing Date	March 24, 2004	
			First Named Inventor	Jun FENG	
			Group Art Unit	1624	
			Examiner Name	Kahsay Hable	
Sheet	12	of	14	Attorney Docket Number	SYR-DPP-IV-5004-C1

KH	ND	WO 04/048352	6/10/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	NE	WO 04/050022	6/17/2004	MERCK & CO., INC.		
	NF	WO 04/050656	6/17/2004	EISAI CO., LTD.		
	NG	WO 04/050658	6/17/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	NH	WO 04/052850	6/24/2004	BRISTOL-MYERS SQUIBB COMPANY		
	NI	WO 04/058266	7/15/2004	MERCK & CO., INC.		
	NJ	WO 04/064778	8/5/2004	MERCK & CO. INC.		
	NK	WO 04/067509	8/12/2004	SANWA KAGAKU KENKYUSHO CO., LTD.		
	NL	WO 04/069182	8/19/2004	MERCK & CO., INC.		
	NM	WO 04/071454	8/26/2004	GUILFORD PHARMACEUTICALS INC.		
	NN	WO 04/075815	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NO	WO 04/075891	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NP	WO 04/076401	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NQ	WO 04/076433	9/10/2004	AIC		
	NR	WO 04/076434	9/10/2004	AIC		
	NS	WO 04/078777	9/16/2004	BIOREXIS PHARMACEUTICAL CORPORATION		
	NT	WO 04/080958	9/23/2004	MERCK & CO. INC.		
	NU	WO 04/083212	9/30/2004	MERCK & CO., INC.		
	NV	WO 04/085661	10/7/2004	MERCK & CO., INC.		
	NW	WO 04/087053	10/14/2004	SYRRX, INC.		
	NX	WO 04/087650	10/14/2004	MERCK & CO. INC.		
	NY	WO 04/087880	10/14/2004	BAYER PHARMACEUTICALS CORPORATION		
	NZ	WO 04/089382	10/21/2004	NOVO NORDISK A/S		
	OA	WO 04/086806	11/11/2004	SUMITOMO PHARMACEUTICALS CO. LTD.		
	OB	WO 04/088825	11/18/2004	PROBIODRUG AG		
	OC	WO 04/089134	11/18/2004	PROSIDION LTD.		
	OD	WO 04/099185	11/18/2004	FUJISAWA PHARMACEUTICAL CO. LTD.		
	OE	WO 04/101514	11/25/2004	TAISHO PHARMACEUTICAL CO., LTD.		
	OF	WO 04/103276	12/2/2004	MERCK & CO., INC.		
	OG	WO 04/103993	12/2/2004	SYRRX, INC.		

Examiner Signature		Date Considered	4/24/2000
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/809,636	
			Filing Date	March 24, 2004	
			First Named Inventor	Jun FENG	
			Group Art Unit	1624	
			Examiner Name	Kahsay Habte	
Sheet	13	of	14	Attorney Docket Number	SYR-DPP-IV-5004-C1

KM	OH	WO 04/110436	12/23/2004	MERCK & CO., INC.		
	OI	WO 04/111041	12/23/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	OJ	WO 04/111051	12/23/2004	BOEHRINGER INGELHEIM INTERNATIONAL GMBH		
	OK	WO 04/112701	12/29/2004	MERCK & CO., INC.		
	OL	WO 05/000848	1/8/2005	F.HOFFMANN-LA ROCHE AG		
	OM	WO 05/003135	1/13/2005	MERCK & CO., INC.		
	ON	WO 05/011581	2/10/2005	MERCK & CO., INC.		
	OO	WO 05/012249	2/10/2005	BRISTOL-MYERS SQUIBB COMPANY		
	OP	WO 05/019168	3/3/2005	PFIZER PRODUCTS INC.		
	OQ	WO 2005/016911	2/24/2005	Symx, Inc.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
KM	OR	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCL. CHEM., Vol. 305, 1972, pages 724-730.				
	OS	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J. ORG. CHEM., Vol. 43, 1978, pages 4069-4074.				
	OT	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 388682 & J. CHEM. SOC., 1952, pages 4985-4990.				
	OU	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389575 & CHEM. BER., Vol. 88, 1968, pages 108-109.				
	OV	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 108-109.				
	OW	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM. BER., Vol. 101, No. 8, 1968, pages 2679-2689.				
	OX	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448869 & CHEM. BER., Vol. 101, No. 8, 1968, pages 2679-2689.				
	OY	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J. CHEM. SOC. PERKIN TRANS. 1, 1980, pages 1370-1380.				

Examiner Signature	<i>[Signature]</i>	Date Considered	4/24/2006
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,636
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
Sheet 14 of 14	Attorney Docket Number	SYR-DPP-IV-5004-C1	

KA	OZ	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1168-1168.	
	PA	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6218070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324.	
	PB	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392448, J.HETEROCYCL.CHEM., Vol. 8, 1971, pages 387-371.	
	PC	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J. PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151.	
	PD	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185.	
	PE	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335083. Database Accession no. 1525341 & J. HETEROCYCL.CHEM., Vol. 12, 1975, pages 683-687.	
	PF	GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-636, XP000889664 compound 1	
	PG	Kesarwani, A. P. et al.: Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581.	
✓	PH	Rauchman, B.S. et al. "2,4-Diamino-5-benzylpyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP002335048 Scheme II	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/24/2006
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.